Mathematical Modeling of Bacterial Kinetics to Predict the Impact of Antibiotic Colonic Exposure and Treatment Duration on the Amount of Resistant Enterobacteria Excreted

PLoS Computational Biology

Volumn 10, Issue 9, 2014, Pages

  Nguyen, Thu Thuy ^a   Guedj, Jeremie ^a   Chachaty, Elisabeth ^b   de Gunzburg, Jean ^c   Andremont, Antoine ^a,d   Mentré, France ^a,d  

^a UNIVERSITÉ PARIS DIDEROT   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c Da Volterra   (France)

^d BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEALTH RISKS; KINETICS; PUBLIC HEALTH;

ANTIBIOTIC CONCENTRATION; COMPLEX RELATIONSHIPS; ENTEROBACTERIA; EXPOSURE DURATIONS; FECAL EXCRETION; INNOVATIVE STRATEGIES; KINETIC MODELS; RESISTANT BACTERIA; RESISTANT STRAINS; TREATMENT DURATION;

ANTIBIOTICS;

CIPROFLOXACIN; PLACEBO; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GROWTH; BACTERIAL KINETICS; BACTERIAL STRAIN; COLON; CONTROLLED STUDY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG TISSUE LEVEL; ENTEROBACTERIACEAE; FECES ANALYSIS; IN VIVO STUDY; INTESTINE FLORA; MATHEMATICAL MODEL; NONHUMAN; PIGLET; PREDICTION; PROSPECTIVE STUDY; SIMULATION; TREATMENT DURATION; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; DRUG EFFECTS; FECES; KINETICS; MICROBIOLOGY; PIG;

ANIMALS; ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; COLON; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; FECES; FLUOROQUINOLONES; KINETICS; MODELS, BIOLOGICAL; SWINE;

EID: 84907579362     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1003840     Document Type: Article

References (49)

1. Zhou L-J, Ying G-G, Liu S, Zhang R-Q, Lai H-J, Chen Z-F, Pan C-G, (2013) Excretion masses and environmental occurrence of antibiotics in typical swine and dairy cattle farms in China. Sci Total Environ 444: 183–195.
2. Li Y-X, Zhang X-L, Li W, Lu X-F, Liu B, Wang J, (2013) The residues and environmental risks of multiple veterinary antibiotics in animal faeces. Environ Monit Assess 85 (3) 2211–2220.
3. Aarestrup FM, Seyfarth AM, Emborg H-D, Pedersen K, Hendriksen RS, Bager F, (2001) Effect of Abolishment of the Use of Antimicrobial Agents for Growth Promotion on Occurrence of Antimicrobial Resistance in Fecal Enterococci from Food Animals in Denmark. Antimicrob Agents Chemother 45 (7) 2054–2059.
4. Marshall BM, Levy SB, (2011) Food animals and antimicrobials: impacts on human health. Clin Microbiol Rev 24 (4) 718–733.
5. Risk Response Network (2013) The Dangers of Hubris on Human Health. Global Risk Report Eighth Edition, World Economic Forum.
6. Collignon P, (2013) Superbugs in food: a severe public health concern. Lancet Infect Dis 13 (8) 641–643.
7. WHO AGISAR (2011). 3rd Revision - WHO list of Critically Important Antimicrobials (CIA) http://www.who.int/foodborne_disease/resistance/cia/en/
8. Donskey CJ, (2004) The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens. Clin Infect Dis 39 (2) 219–226.
9. Moreno E, Andreu A, Pigrau C, Kuskowski MA, Johnson JR, et al. (2008) Relationship between Escherichia coli strains causing acute cystitis in women and the fecal E. coli population of the host. J Clin Microbiol 46 (8) 2529–2534.
10. Guillot JF, Chaslus-Dancla E, Lafont JP, (1977) Spontaneous implantation of antibiotic-resistant Enterobacteriaceae in the digestive tract of chickens in the absence of selective pressure. Antimicrob Agents Chemother 12 (6) 697–702.
11. Aubry-Damon H, Grenet K, Sall-Ndiaye P, Che D, Cordeiro E, et al. (2004) Antimicrobial resistance in commensal flora of pig farmers. Emerging Infect Dis 10 (5) 873–879.
12. Pecquet S, Ravoire S, Andremont A, (1990) Faecal excretion of ciprofloxacin after a single oral dose and its effect on faecal bacteria in healthy volunteers. J Antimicrob Chemother 26 (1) 125–129.
13. Rice LB, (2012) Gastrointestinal Bacteria Will Have Its Way. J Infect Dis 206 (9) 1334–1335.
14. De Lastours V, Cambau E, Guillard T, Marcade G, Chau F, et al. (2012) Diversity of Individual Dynamic Patterns of Emergence of Resistance to Quinolones in Escherichia coli From the Fecal Flora of Healthy Volunteers Exposed to Ciprofloxacin. J Infect Dis 206 (9) 1399–1406.
15. Nguyen TT, Chachaty E, Huy C, Cambier C, de Gunzburg J, et al. (2012) Correlation between fecal concentrations of ciprofloxacin and fecal counts of resistant Enterobacteriaceae in piglets treated with ciprofloxacin: toward new means to control the spread of resistance? Antimicrob Agents Chemother 56 (9) 4973–4975.
16. Carlet J, (2012) The gut is the epicentre of antibiotic resistance. Antimicrob Resist Infect Control 1 (1) 39.
17. Khoder M, Tsapis N, Domergue-Dupont V, Gueutin C, Fattal E, (2010) Removal of residual colonic ciprofloxacin in the rat by activated charcoal entrapped within zinc-pectinate beads. European Journal of Pharmaceutical Sciences 41 (2) 281–288.
18. Ferran AA, Toutain P-L, Bousquet-Mélou A, (2011) Impact of early versus later fluoroquinolone treatment on the clinical; microbiological and resistance outcomes in a mouse-lung model of Pasteurella multocida infection. Vet Microbiol 148 (2–4) 292–297.
19. Meagher AK, Forrest A, Dalhoff A, Stass H, Schentag JJ, (2004) Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin. Antimicrob Agents Chemother 48 (6) 2061–2068.
20. De Gelder L, Ponciano JM, Abdo Z, Joyce P, Forney LJ, et al. (2004) Combining mathematical models and statistical methods to understand and predict the dynamics of antibiotic-sensitive mutants in a population of resistant bacteria during experimental evolution. Genetics 168 (3) 1131–1144.
21. Campion JJ, McNamara PJ, Evans ME, (2005) Pharmacodynamic modeling of ciprofloxacin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 49 (1) 209–219.
22. Nielsen EI, Viberg A, Löwdin E, Cars O, Karlsson MO, et al. (2007) Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments. Antimicrob Agents Chemother 51 (1) 128–136.
23. Bulitta JB, Yang JC, Yohonn L, Ly NS, Brown SV, et al. (2010) Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model. Antimicrob Agents Chemother 54 (5) 2051–2062.
24. Bhagunde P, Singh R, Ledesma KR, Chang K-T, Nikolaou M, et al. (2011) Modelling biphasic killing of fluoroquinolones: guiding optimal dosing regimen design. J Antimicrob Chemother 66 (5) 1079–1086.
25. Jumbe N, Louie A, Leary R, Liu W, Deziel MR, et al. (2003) Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest 112 (2) 275–285.
26. Guedj J, Thiébaut R, Commenges D, (2007) Maximum likelihood estimation in dynamical models of HIV. Biometrics 63 (4) 1198–1206.
27. Andersson DI, Hughes D, (2010) Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol 8 (4) 260–271.
28. Ruimy R, Brisabois A, Bernede C, Skurnik D, Barnat S, et al. (2010) Organic and conventional fruits and vegetables contain equivalent counts of Gram-negative bacteria expressing resistance to antibacterial agents. Environ Microbiol 12 (3) 608–615.
29. Matic I, Radman M, Taddei F, Picard B, Doit C, et al. (1997) Highly variable mutation rates in commensal and pathogenic Escherichia coli. Science 277 (5333) 1833–1834.
30. Komp Lindgren P, Karlsson A, Hughes D, (2003) Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob Agents Chemother 47 (10) 3222–3232.
31. Komp Lindgren P, Marcusson LL, Sandvang D, Frimodt-Møller N, Hughes D, (2005) Biological cost of single and multiple norfloxacin resistance mutations in Escherichia coli implicated in urinary tract infections. Antimicrob Agents Chemother 49 (6) 2343–2351.
32. Andremont A, (2003) Commensal flora may play key role in spreading antibiotic resistance. ASM News (69) 601–607.
33. Wielgoss S, Barrick JE, Tenaillon O, Cruveiller S, Chane-Woon-Ming B, et al. (2011) Mutation Rate Inferred From Synonymous Substitutions in a Long-Term Evolution Experiment With Escherichia coli. G3 (Bethesda) 1 (3) 183–186.
34. Pinheiro JC, Bates DM (2000) Mixed-Effects Models in S and S-PLUS. Springer Verlag.
35. Kuhn E, Lavielle M, (2005) Maximum likelihood estimation in nonlinear mixed effects models. Comput Stat Data Anal 49 (4) 1020–38.
36. Lavielle M, Samson A, Karina Fermin A, Mentré F, (2011) Maximum likelihood estimation of long-term HIV dynamic models and antiviral response. Biometrics 67 (1) 250–259.
37. Samson A, Lavielle M, Mentré F, (2006) Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: Application to HIV dynamics model. Comput Stat Data Anal 51 (3) 1562–1574.
38. Haley M, (2009) U.S.-Canadian Hog Trade: Market Integration at Work. Amber Waves 37–38.
39. Nyachoti CM, Arntfield SD, Guenter W, Cenkowski S, Opapeju FO, (2006) Effect of micronized pea and enzyme supplementation on nutrient utilization and manure output in growing pigs. J ANIM SCI 84 (8) 2150–2156.
40. O'Regan E, Quinn T, Frye JG, Pages J-M, Porwollik S, et al. (2010) Fitness Costs and Stability of a High-Level Ciprofloxacin Resistance Phenotype in Salmonella enterica Serotype Enteritidis: Reduced Infectivity Associated with Decreased Expression of Salmonella Pathogenicity Island 1 Genes. Antimicrob Agents Chemother 54 (1) 367–374.
41. Wiuff C, Lykkesfeldt J, Svendsen O, Aarestrup FM, (2003) The effects of oral and intramuscular administration and dose escalation of enrofloxacin on the selection of quinolone resistance among Salmonella and coliforms in pigs. Res Vet Sci 75 (3) 185–193.
42. Naber KG, (1999) Short-term therapy of acute uncomplicated cystitis. Curr Opin Urol (1) 57–64.
43. Zani EL, Clark OAC, Rodrigues Netto N, Jr (2011) Antibiotic prophylaxis for transrectal prostate biopsy. Cochrane Database Syst Rev (5) CD006576.
44. Andersson DI, Levin BR, (1999) The biological cost of antibiotic resistance. Curr Opin Microbiol 2 (5) 489–493.
45. Anderson VR, Perry CM, (2008) Levofloxacin: a review of its use as a high-dose, short-course treatment for bacterial infection. Drugs 68 (4) 535–565.
46. Dimopoulos G, Poulakou G, Pneumatikos IA, Armaganidis A, Kollef MH, et al. (2013) Short- versus long-duration antibiotic regimens for ventilator-associated pneumonia: a systematic review and meta-analysis. Chest 144 (6) 1759–1767.
47. Sayah-Jeanne S, Chachaty E, Nguyen TT, V A, de Gunzburg J, Andremont A (2012) Decrease of levofloxacin concentrations in experimental dogs using DAV132, an oral adsorbent delivered to the ileum/colon. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC.
48. Khoder M, Tsapis N, Huguet H, Besnard M, Gueutin C, et al. (2009) Removal of ciprofloxacin in simulated digestive media by activated charcoal entrapped within zinc-pectinate beads. Int J Pharm 379 (2) 251–259.
49. Wiuff C, Lykkesfeldt J, Aarestrup FM, Svendsen O, (2002) Distribution of enrofloxacin in intestinal tissue and contents of healthy pigs after oral and intramuscular administrations. J Vet Pharmacol Ther 25 (5) 335–342.